Reata Pharmaceuticals Inc (NASDAQ:RETA) insider Elaine Castellanos sold 3,588 shares of Reata Pharmaceuticals stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $102.00, for a total transaction of $365,976.00. Following the completion of the sale, the insider now owns 5,726 shares in the company, valued at approximately $584,052. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NASDAQ:RETA traded down $0.73 during midday trading on Thursday, hitting $91.35. The company’s stock had a trading volume of 243,165 shares, compared to its average volume of 236,918. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 2.10. The company has a market cap of $2.75 billion, a P/E ratio of -31.83 and a beta of 3.15. Reata Pharmaceuticals Inc has a 12-month low of $19.31 and a 12-month high of $104.53.
Get Reata Pharmaceuticals alerts:Reata Pharmaceuticals (NASDAQ:RETA) last posted its quarterly earnings results on Thursday, February 28th. The company reported ($0.86) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.07) by $0.21. On average, analysts expect that Reata Pharmaceuticals Inc will post -4.39 earnings per share for the current year.
Several analysts have recently issued reports on the stock. Cantor Fitzgerald set a $100.00 target price on shares of Reata Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 7th. BidaskClub lowered shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 15th. ValuEngine upgraded shares of Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Finally, Zacks Investment Research lowered shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, November 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $100.33.
Several large investors have recently bought and sold shares of the company. American Century Companies Inc. lifted its stake in shares of Reata Pharmaceuticals by 36.5% in the fourth quarter. American Century Companies Inc. now owns 41,124 shares of the company’s stock worth $2,307,000 after buying an additional 11,000 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Reata Pharmaceuticals by 6.0% in the fourth quarter. Geode Capital Management LLC now owns 192,306 shares of the company’s stock worth $10,788,000 after buying an additional 10,958 shares in the last quarter. Sofinnova Investments Inc. purchased a new position in shares of Reata Pharmaceuticals in the fourth quarter worth about $8,863,000. UBS Oconnor LLC lifted its stake in shares of Reata Pharmaceuticals by 39.6% in the fourth quarter. UBS Oconnor LLC now owns 17,178 shares of the company’s stock worth $964,000 after buying an additional 4,874 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Reata Pharmaceuticals by 36.3% in the fourth quarter. Millennium Management LLC now owns 135,658 shares of the company’s stock worth $7,610,000 after buying an additional 36,116 shares in the last quarter. 53.65% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/4204643/reata-pharmaceuticals-inc-reta-insider-elaine-castellanos-sells-3588-shares.html.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.
Featured Story: Insider Trading
No comments:
Post a Comment